Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
Primary Objectives:
Full description
This is an open-label, repeat-dose, multicenter extension trial of HZNP-HZN-825-301. Participants who complete the double-blind Treatment Period (Week 52) in Trial HZNP-HZN-825-301 will be eligible to enter this 52-week extension trial. Participants entering this extension trial will complete the Week 52 Visit activities in HZNP-HZN-825-301 and will not complete the Safety Follow-up Visit 4 weeks after the last dose of trial drug in HZNP-HZN-825-301.
Acquired from Horizon in 2024.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
246 participants in 1 patient group
Loading...
Central trial contact
Horizon Therapeutics
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal